Cancer statistics for adolescents and young adults, 2020
2020/09/17 by Kimberly D. Miller, Miranda Fidler‐Benaoudia, Miranda M Fidler-Benaoudia +5 · 1,222 citations
Medicine · #Acute Lymphoblastic Leukemia research #Breast cancer #Cancer #Cancer Risks and Factors #Cancer registry #Cervical cancer #Childhood Cancer Survivors' Quality of Life #Demography #Environmental health #Gerontology #Incidence (geometry) #Internal medicine #Medicine #Obesity #Population #Thyroid cancer #Uterine cancer #Young adult
paper · pdf · doi:10.3322/caac.21637
published in CA A Cancer Journal for Clinicians 70(6), 443-459 (Wiley)
openalex publication_date 2020/09/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
Abstract
Cancer statistics for adolescents and young adults (AYAs) (aged 15-39 years) are often presented in aggregate, masking important heterogeneity. The authors analyzed population-based cancer incidence and mortality for AYAs in the United States by age group (ages 15-19, 20-29, and 30-39 years), sex, and race/ethnicity. In 2020, there will be approximately 89,500 new cancer cases and 9270 cancer deaths in AYAs. Overall cancer incidence increased in all AYA age groups during the most recent decade (2007-2016), largely driven by thyroid cancer, which rose by approximately 3% annually among those aged 20 to 39 years and 4% among those aged 15 to 19 years. Incidence also increased in most age groups for several cancers linked to obesity, including kidney (3% annually across all age groups), uterine corpus (3% in the group aged 20-39 years), and colorectum (0.9%-1.5% in the group aged 20-39 years). Rates declined dramatically for melanoma in the group aged 15 to 29 years (4%-6% annually) but remained stable among those aged 30 to 39 years. Overall cancer mortality declined during 2008 through 2017 by 1% annually across age and sex groups, except for women aged 30 to 39 years, among whom rates were stable because of a flattening of declines in female breast cancer. Rates increased for cancers of the colorectum and uterine corpus in the group aged 30 to 39 years, mirroring incidence trends. Five-year relative survival in AYAs is similar across age groups for all cancers combined (range, 83%-86%) but varies widely for some cancers, such as acute lymphocytic leukemia (74% in the group aged 15-19 years vs 51% in the group aged 30-39 years) and brain tumors (77% vs 66%), reflecting differences in histologic subtype distribution and treatment. Progress in reducing cancer morbidity and mortality among AYAs could be addressed through more equitable access to health care, increasing clinical trial enrollment, expanding research, and greater alertness among clinicians and patients for early symptoms and signs of cancer. Further progress could be accelerated with increased disaggregation by age in research on surveillance, etiology, basic biology, and survivorship.
Citations
Cited by
- Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
- The impact of a single HIIT intervention on the mobilization of NK cells and ILCs in adolescents and young adults (AYA) undergoing cancer treatment: an interventional controlled trial
- Allura Red AC is a xenobiotic. Is it also a carcinogen?
- MultiTumor Analyzer (MTA-20–55): A network for efficient classification of detected brain tumors from MRI images
- Is there a relationship between tumour aggressiveness and ovarian stimulation outcomes in adolescent and young adult patients with lymphoma?
- Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15-39 Years): A Population-Based Study in The Netherlands 1990-2016. [europepmc]
- Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy. [europepmc]
- CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. [europepmc]
- The global, regional, and national burden of cancer among adolescents and young adults in 204 countries and territories, 1990-2019: a population-based study. [europepmc]
- The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. [europepmc]
- Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities. [europepmc]
- Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. [europepmc]
- Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019. [europepmc]
- CircRNA: A novel potential strategy to treat thyroid cancer (Review). [europepmc]
- Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview. [europepmc]
- Risk Factors and a Prediction Model of Lateral Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma Patients With 1-2 Central Lymph Node Metastases. [europepmc]
- Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. [europepmc]
- Nutraceuticals and Cancer: Potential for Natural Polyphenols. [europepmc]
- The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. [europepmc]
- Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. [europepmc]
- Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. [europepmc]
- A Systematic Review of Ovarian Tissue Transplantation Outcomes by Ovarian Tissue Processing Size for Cryopreservation. [europepmc]
- The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. [europepmc]
- Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. [europepmc]
- Targeting Apoptotic Pathway of Cancer Cells with Phytochemicals and Plant-Based Nanomaterials. [europepmc]
- Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. [europepmc]
- Survival Trends Among Adolescents and Young Adults Diagnosed With Cancer in the United States: Comparisons With Children and Older Adults. [europepmc]
- VEGFA/NRP-1/GAPVD1 axis promotes progression and cancer stemness of triple-negative breast cancer by enhancing tumor cell-macrophage crosstalk. [europepmc]
- Global cancer statistics for adolescents and young adults: population based study. [europepmc]
- Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. [europepmc]
Related